TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18574086

Group type: EXPERIMENTAL
Intervention: Interleukin 2 (IL-2)
Number of subjects: 582

Group type: COMPARATOR
Intervention: No IL-2
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 582
Study: 16096451

Group type: EXPERIMENTAL
Intervention: LY315920NA/S‐5920 (n = 188)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo (n = 185)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: LY315920NA/S‐5920
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 12460222

Group type: EXPERIMENTAL
Intervention: Shared decision-making with doctor
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Active role in decision-making
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Information about benefits of tests and treatment
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Desire for information about false test results
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Desire for information about test side-effects
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Information not provided about false results
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Information not provided about side-effects
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Anxiety about false results
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Anxiety about side-effects
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Desire for information about false results despite anxiety
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Desire for information about side-effects despite anxiety
Number of subjects: 652
Study: 9607554

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 3‐month depot (LAD‐3M)
Number of subjects: 62
Study: 7890072

Group type: EXPERIMENTAL
Intervention: Partial zona dissection
Number of subjects: 32

Group type: COMPARATOR
Intervention: IVF
Number of subjects: 32
Study: 2646729

Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone (IVMP) pulse therapy (1 gm) for group 1 (one or two courses) and repeated pulses for group 2 (four to 21 months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Repeated pulses of 1 gm of IVMP for group 2
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (group 3) with 21 randomized patients
Number of subjects: 14
Study: 282943

Group type: EXPERIMENTAL
Intervention: Daytime (awake) mucociliary clearance
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nighttime (asleep) mucociliary clearance
Number of subjects: 7
Study: 29747706

Group type: EXPERIMENTAL
Intervention: Guided online CBT‐I and sleep diary monitoring (i‐Sleep)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sleep diary monitoring only (Control)
Number of subjects: 104
Study: 28272911

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables (≥14 cups/week)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 69
Study: 25733500

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 to 20 mg/ml for 5 to 7 days)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Azithromycin (5-μg disk)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Azithromycin MIC of ≤ 16 μg/ml or disk inhibition zone size of ≥ 13 mm
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: S. Typhi isolates
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: S. Paratyphi A isolates
Number of subjects: 214
Study: 23835341

Group type: EXPERIMENTAL
Intervention: TNF‐α infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 8
Study: 22692843

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous every 6 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 19399538

Group type: EXPERIMENTAL
Intervention: Mini-open approach (MO group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classic posterior approach (CL group)
Number of subjects: 30
Study: 17318036

Group type: EXPERIMENTAL
Intervention: Exercise (10 minutes, 3 times a day, 5 days a week at 50% to 60% heart rate reserve)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Exercise
Number of subjects: 24
Study: 15193831

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/die)
Number of subjects: 44
Study: 11577621

Group type: EXPERIMENTAL
Intervention: Imagining worked examples that emphasized imagining procedures and concepts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Studying worked examples that emphasized understanding and remembering procedures and concepts
Number of subjects: 0
Study: 9283670

Group type: EXPERIMENTAL
Intervention: Flexible sheath
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard sheath
Number of subjects: 107
Study: 8496357

Group type: EXPERIMENTAL
Intervention: Weight-relieving caliper
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal femoral varus osteotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (bed rest and skin traction)
Number of subjects: 0
Study: 2881825

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms initially as an intravenous bolus and then 250 micrograms/h via infusion)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline 0.15 M)
Number of subjects: 15
Study: 30726962

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuing usual care
Number of subjects: 0
Study: 29514706

Group type: EXPERIMENTAL
Intervention: ASCTAug (high-dose melphalan with ixazomib)
Number of subjects: 406

Group type: COMPARATOR
Intervention: ASCTCon (high-dose melphalan)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Consolidation with two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression
Number of subjects: 406

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 406
Study: 26897513

Group type: EXPERIMENTAL
Intervention: RT‐CT (Chemoradiation)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: RT‐HT (Radiotherapy combined with hyperthermia)
Number of subjects: 87
Study: 25240761

Group type: EXPERIMENTAL
Intervention: Tasquinimod (TASQ)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 22377973

Group type: EXPERIMENTAL
Intervention: Gastroretentive ER formulation with immediate release component (IR/ER)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Gastroretentive ER formulation without immediate release component (ER)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional ER tablet (C-ER)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Finger tapping test
Number of subjects: 14
Study: 20637388

Group type: EXPERIMENTAL
Intervention: End-tidal CO2 measured by a microstream capnometer
Number of subjects: 43
Study: 17585027

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg) capsules daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 16129717

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and physical activity program)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 15253389

Group type: EXPERIMENTAL
Intervention: Relapse cases (PB leprosy)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Relapse cases (MB leprosy)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: History of contact with an active leprosy patient and irregular treatment
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Initial BI of 3+
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control cases (Not relapse)
Number of subjects: 256
Study: 10955437

Group type: EXPERIMENTAL
Intervention: Oestradiol-releasing vaginal ring for 24 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Oestriol pessaries 0.5 mg every second day for 24 weeks
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Oestradiol-releasing vaginal ring
Number of subjects: 251

Group type: COMPARATOR
Intervention: Oestriol pessaries
Number of subjects: 251
Study: 8837670

Group type: EXPERIMENTAL
Intervention: Perfume provocation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carbon filter mask during perfume provocation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo provocation
Number of subjects: 9
Study: 1408546

Group type: COMPARATOR
Intervention: Water
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Balanced formula
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Carbohydrate (lactose)
Number of subjects: 53
Study: 3973310

Group type: EXPERIMENTAL
Intervention: Food challenges (71 challenges with doses ranging from 5 to 100 gm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (12 placebos administered)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Follow-up survey (10-12 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Positive food challenges
Number of subjects: 25
Study: 3543241

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (FAC: fluorouracil, doxorubicin, cyclophosphamide) in a protected environment with prophylactic antibiotics
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard hospital room treatment
Number of subjects: 33
Study: 31091611

Group type: EXPERIMENTAL
Intervention: sIPV+sIPV+bOPV
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: sIPV+wIPV+bOPV
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: wIPV+sIPV+bOPV
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: wIPV+wIPV+bOPV
Number of subjects: 151
Study: 28486879

Group type: EXPERIMENTAL
Intervention: Single novel imaginal intervention session
Number of subjects: 98

Group type: COMPARATOR
Intervention: 15‐min meditation (control group)
Number of subjects: 98
Study: 26519708

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 200

Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 200
Study: 24555234

Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 0
Study: 21470288

Group type: EXPERIMENTAL
Intervention: (18)FDG‐PET/CT scan
Number of subjects: 88
Study: 18337077

Group type: EXPERIMENTAL
Intervention: Long pulmonary rehabilitation programme (18 weeks)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: More previous hospital admissions
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Higher Medical Research Council (MRC) dyspnoea score
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Enduring a long journey to the PR centre
Number of subjects: 239

Group type: COMPARATOR
Intervention: Short pulmonary rehabilitation programme (6 weeks)
Number of subjects: 239
Study: 16502116

Group type: EXPERIMENTAL
Intervention: risedronate
Number of subjects: 27

Group type: COMPARATOR
Intervention: antithyroid drug only
Number of subjects: 27
Study: 12772816

Group type: EXPERIMENTAL
Intervention: Pemirolast potassium 0.1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nedocromil sodium 2%
Number of subjects: 80
Study: 10703904

Group type: EXPERIMENTAL
Intervention: Belladonna 7cH and X‐ray 15cH
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9258850

Group type: EXPERIMENTAL
Intervention: All-out effort against an applied resistance of 7.5% of body weight (test 1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Constant pace of 55% of the peak pedal rate of test 1 against a resistance of 10.9 +/- 0.4% of body weight (test 2)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All-out effort against the greater resistance (test 3)
Number of subjects: 7
Study: 8479036

Group type: EXPERIMENTAL
Intervention: Artery-preserved group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Artery-ligated group
Number of subjects: 34
Study: 3541963

Group type: EXPERIMENTAL
Intervention: Mesotrin (2.5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoptin
Number of subjects: 30
Study: 31914685

Group type: EXPERIMENTAL
Intervention: 12-week exercise training (aerobic exercise or combination of aerobic exercise and resistance training)
Number of subjects: 16

Group type: COMPARATOR
Intervention: NDD-CKD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 16
Study: 30556713

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 270
Study: 27977757

Group type: EXPERIMENTAL
Intervention: DHA plus vitamin D (500 mg DHA and 800 IU vitamin D daily)
Number of subjects: 41
Study: 23930984

Group type: EXPERIMENTAL
Intervention: Universal zinc plus vitamin A supplementation (VAZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin A alone (VA)
Number of subjects: 0
Study: 23002493

Group type: EXPERIMENTAL
Intervention: Patients who were white
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Patients administered a selective serotonin reuptake inhibitor
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Patients administered two antipsychotic agents
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Patients administered an opiate
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Patients administered a diuretic non-antihypertensive agent
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Home-based wheelchair use
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Patients designated as 'high' fall risk
Number of subjects: 784
Study: 19969286

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 73
Study: 19080398

Group type: EXPERIMENTAL
Intervention: Anaerobic Threshold (AT) group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) group
Number of subjects: 54
Study: 15942629

Group type: EXPERIMENTAL
Intervention: ILF (irinotecan plus high-dose 5-fluorouracil and leucovorin)
Number of subjects: 114

Group type: COMPARATOR
Intervention: ELF (etoposide plus 5-fluorouracil and leucovorin)
Number of subjects: 114
Study: 9164899

Group type: EXPERIMENTAL
Intervention: Endurance exercise training in patients with normal left ventricular (LV) function
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance exercise training in patients with depressed left ventricular (LV) function
Number of subjects: 20
Study: 10362612

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms/kg rhGH
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 5.0 micrograms/kg rhGH
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Higher doses of rhGH (10.0 and 20.0 micrograms/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.25 micrograms/kg rhGH
Number of subjects: 21
Study: 7566950

Group type: EXPERIMENTAL
Intervention: Conservative treatment (nitroglycerin, calcium channel blocker or both)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (EST)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transduodenal sphincterotomy
Number of subjects: 64
Study: 1982983

Group type: EXPERIMENTAL
Intervention: 50 mg BCH 069 by intravenous injection for 6 weeks 3 times weekly
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 50 mg BCH 069 by subcutaneous injection for 4 weeks 3 times weekly
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 7000249

Group type: EXPERIMENTAL
Intervention: Colostomy irrigation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spontaneous action
Number of subjects: 30
Study: 29538666

Group type: EXPERIMENTAL
Intervention: Childhood obesity risk information plus a personalized family history‐based risk estimate for their child
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Childhood obesity risk information
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control information
Number of subjects: 221
Study: 26889993

Group type: EXPERIMENTAL
Intervention: Arthroplasty using artificial cervical disks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Arthrodesis using zero‐profile devices
Number of subjects: 30
Study: 24368867

Group type: EXPERIMENTAL
Intervention: Synchronized Demand Oxygen Delivery (SDOD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous Flow Oxygen (CFO)
Number of subjects: 10
Study: 22242712

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate (MAL)‐PDT
Number of subjects: 8
Study: 20227123

Group type: EXPERIMENTAL
Intervention: 68-Gy radiotherapy
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: 78-Gy radiotherapy
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Dose escalation based on PSA-level groupings
Number of subjects: 664

Group type: COMPARATOR
Intervention: High-dose radiotherapy
Number of subjects: 664
Study: 17513327

Group type: EXPERIMENTAL
Intervention: Benazepril 0.2 mg/kg per day (ACE-I)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 15727682

Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (25 g protein and 60 mg isoflavones)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (unspecified control foods)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both soy and control groups
Number of subjects: 87
Study: 11901278

Group type: EXPERIMENTAL
Intervention: Diuretic-based treatment
Number of subjects: 4718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4718

Group type: EXPERIMENTAL
Intervention: Adjusted follow-up scores based on baseline data
Number of subjects: 4718

Group type: EXPERIMENTAL
Intervention: Baseline data adjustment
Number of subjects: 4718
Study: 9843546

Group type: EXPERIMENTAL
Intervention: High-GI potato (HGI trial)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-GI pasta (LGI trial)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-energy jelly (Con trial)
Number of subjects: 6
Study: 7515999

Group type: EXPERIMENTAL
Intervention: Urapidil (35‐50 mg, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diltiazem (25 mg, n = 10)
Number of subjects: 20
Study: 2648447

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy (psychoanalytically oriented)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Viloxazine (an antidepressant)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lormetazepam (a benzodiazepine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine (a methyl donor with antidepressive properties)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 29976474

Group type: EXPERIMENTAL
Intervention: Telephone nursing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone nursing recommendation (highest level of care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone nursing recommendation (self-care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compliance to nurse's recommendation
Number of subjects: 0
Study: 27603398

Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin orally administered 2 hours before surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo orally administered 2 hours before surgery
Number of subjects: 44
Study: 24687509

Group type: EXPERIMENTAL
Intervention: Primaquine 30 mg (base)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chloroquine 600 mg (base)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coadministration of primaquine and chloroquine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chloroquine with primaquine
Number of subjects: 16
Study: 22676397

Group type: COMPARATOR
Intervention: Preladenant (5-200 mg single doses)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Preladenant (10-200 mg once daily for 10 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 20711565

Group type: EXPERIMENTAL
Intervention: 10-Hz SSVEP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15-Hz SSVEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-Hz competing stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: 60-Hz competing stimulus
Number of subjects: 0
Study: 18346973

Group type: EXPERIMENTAL
Intervention: Diabetes Problem Solving Interview (DPSI) for caregivers
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Diabetes Problem Solving Interview (DPSI) for youths
Number of subjects: 223
Study: 16385906

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy treatment B
Number of subjects: 0
Study: 12585165

Group type: EXPERIMENTAL
Intervention: Puerarin 500 mg once a day for 3 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 76
Study: 9105229

Group type: EXPERIMENTAL
Intervention: 0.015-0.32 g/kg 5% rHb1.1 (n = 34)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 5% human serum albumin (HSA; n = 14)
Number of subjects: 48
Study: 2029982

Group type: EXPERIMENTAL
Intervention: Kava Extract WS 1490 (3 X 100 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7195257

Group type: EXPERIMENTAL
Intervention: Praziquantel (EMBAY 8440, Biltricide)
Number of subjects: 153
Study: 31640092

Group type: EXPERIMENTAL
Intervention: LIBRA index
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: LIBRA-2
Number of subjects: 308
Study: 28420440

Group type: EXPERIMENTAL
Intervention: AHSCT treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin-only treatment
Number of subjects: 18
Study: 25403881

Group type: EXPERIMENTAL
Intervention: Endolymphatic duct blockage (EDB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Endolymphatic sac decompression (ESD)
Number of subjects: 57
Study: 25000742

Group type: EXPERIMENTAL
Intervention: Nurse-designed mobile health education application on Pap testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pamphlet on Pap testing
Number of subjects: 0
Study: 22976507

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 19273451

Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Abatacept 2 mg/kg
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 18086061

Group type: EXPERIMENTAL
Intervention: Dermicol-P35
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-animal-stabilized hyaluronic acid (NASHA)
Number of subjects: 149